EU Medical Device Regulation (MDR) – Chemical Content Restrictions
ENFORCEMENT TIMELINE
Full application since May 26, 2021 (1,000 ppm limit on CMR substances and endocrine disruptors in medical devices)
Overview
The EU Medical Device Regulation (MDR, Regulation (EU) 2017/745) is a directly applicable regulation governing the safety and performance of medical devices placed on the EU market, and became fully applicable on May 26, 2021. Beyond quality and safety standards, the regulation includes strict content-restriction requirements for chemical substances used in medical device components (Annex I, Section 10.4), setting a hazardous substance management standard that goes beyond the RoHS Directive for medical device manufacturers.
For components and parts that enter the patient's body, form part of a pathway for transporting or introducing fluids, or come into direct contact with the human body, the concentration of carcinogenic, mutagenic, or reprotoxic substances (CMR substances classified as Category 1A or 1B under the EU CLP Regulation) and endocrine disruptors (EDs, including certain phthalate plasticizers) must not exceed 0.1% by weight (1,000 ppm).
Enforcement Timeline
May 2017: The previous Medical Device Directive (MDD) is repealed and the new MDR (EU) 2017/745 formally enters into force, beginning a three-year transition period.
2020: Full application is granted a one-year special extension in response to the COVID-19 pandemic.
May 26, 2021: The MDR becomes fully applicable, ending the transition period and making its requirements mandatory.
March 2023: To avoid medical supply shortages caused by congestion at conformity assessment bodies, the compliance transition deadline for certain existing products is granted a phased special extension to 2027–2028.
From 2025: The phase requiring complete elimination of phthalate plasticizers (DEHP) from medical polymers and tubing begins in earnest, alongside full-scale supply of alternative medical materials.
Business Impact
Phthalate plasticizers (DEHP), long used in flexible PVC medical tubing such as implantable catheters and cardiopulmonary bypass tubing, must be replaced with phthalate-free alternatives (such as TOTM), polyurethane, or silicone materials to meet the MDR's 1,000 ppm threshold. Because a material change requires repeating cytotoxicity and biocompatibility testing (re-certification for clinical conformity), this involves substantial additional cost and an application process spanning several years.
Component manufacturers must maintain the operational capability to respond to rigorous content surveys from medical device manufacturers (OEM customers) — full-composition disclosure requests — providing verified content data down to screws, gaskets, and exterior adhesives for any substance present above 0.1%. Building a dedicated chemical content survey scheme for medical devices, such as chemSHERPA or IMDS, is also a challenge companies must address.